NK News and Press, NantKwest From 11/22/20

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32 nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020. NantKwest Executive Chairman Patrick Soon-Shiong, ...

Results from the low dose cohort in a Phase 1 clinical trial in 20 healthy volunteers showed no serious adverse events associated with ImmunityBio's second-generation bivalent human adenovirus COVID-19 vaccine candidate hAd5.The study is assessing the safety and reactogenicity of two shots ad...

First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design ImmunityBio, a privately-held ...

Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...

Study shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2 infection, demonstrating that the S and N antigens from the vaccine are recognized by SARS-COV-2 reactive human T cells St...

Biogen BIIB -28% after FDA advisory committee snub of Alzheimer’s drug.Quidel (QDEL) -26%.HighPoint Resources HPR -25% on Q3 earnings release.Co-Diagnostics CODX -24%.Enlivex Therapeutics (ENLV) -21%.Liquidia Technologies LQDA -20% on Q3 earnings...

Our proprietary POWR Ratings system evaluates stocks on a variety of metrics. It recently downgraded several stocks to "Sell" or "Strong" Sell ratings, including Macy's (M), NantKwest (NK), Oxford Industries (OXM), and NextCure (NXTC). Read more to learn why you should avoid them. The ...

NantKwest (NK) appointed healthcare industry veteran Richard Adcock as its CEO, effective immediately.Richard will assume the role of CEO from Dr. Patrick Soon-Shiong, who will become the board's executive chairman; Dr. Soon-Shiong remains the largest shareholder in NantKwest.M...